|
|
Silvia Espejel, Garrett R. Roll, K. John McLaughlin, Andrew Y. Lee, Jenny Y. Zhang, Diana J. Laird, Keisuke Okita, Shinya Yamanaka, Holger Willenbring
J Clin Invest. 2010;
120(9):3120
doi:10.1172/JCI43267
Abstract |
Full text
| PDF
| Supplemental material

T
he ability to generate induced pluripotent stem (iPS) cells from a patient’s somatic cells has provided a foundation for organ regeneration without the need for immune suppression. However, it has not been established that the differentiated progeny of iPS cells can effectively reverse failure of a vital organ. Here, we examined whether iPS cell–derived hepatocytes have both the functional and proliferative capabilities needed for liver regeneration in mice with fumarylacetoacetate hydrolase deficiency. To avoid biases resulting from random genomic integration, we used iPS cells generated without viruses. To exclude compensation by hepatocytes not derived from iPS cells, we generated chimeric mice in which all hepatocytes were iPS cell derived. In vivo analyses showed that iPS cells were intrinsically able to differentiate into fully mature hepatocytes that provided full liver function. The iPS cell–derived hepatocytes also replicated the unique proliferative capabilities of normal hepatocytes and were able to regenerate the liver after transplantation and two-thirds partial hepatectomy. Thus, our results establish the feasibility of using iPS cells generated in a clinically acceptable fashion for rapid and stable liver regeneration.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(18)
| Title and authors |
Publication |
Year |
Cell therapies for liver diseases
Yue Yu, James E. Fisher, Joseph B. Lillegard, Brian Rodysill, Bruce Amiot, Scott L. Nyberg
|
Liver Transpl
|
2012 |
Stem cells in liver diseases and cancer: Recent advances on the path to new therapies
C. Bart Rountree, Lopa Mishra, Holger Willenbring
|
Hepatology
|
2012 |
Increased Reprogramming Capacity of Mouse Liver Progenitor Cells, Compared With Differentiated Liver Cells, Requires the BAF Complex
Alexander Kleger, Pallavi Mahaddalkar, Sarah–Fee Katz, André Lechel, Jin Young Ju, Komal Loya, Qiong Lin, Daniel Hartmann, Stefan Liebau, Johann Kraus
|
Gastroenterology
|
2012 |
Fetal liver cell transplantation as a potential alternative to whole liver transplantation?
Michael Oertel
|
J Gastroenterol
|
2011 |
Modeling and therapy of human liver diseases using induced pluripotent stem cells: How far have we come?
Alejandro Soto-Gutierrez, Edgar Tafaleng, Victoria Kelly, Jayanta Roy-Chowdhury, Ira J. Fox
|
Hepatology
|
2011 |
Purpose-driven biomaterials research in liver-tissue engineering
Abhishek Ananthanarayanan, Balakrishnan Chakrapani Narmada, Xuejun Mo, Michael McMillian, Hanry Yu
|
Trends in Biotechnology
|
2011 |
New concepts in liver regeneration
Kimberly J Riehle, Yock Y Dan, Jean S Campbell, Nelson Fausto
|
Journal of Gastroenterology and Hepatology
|
2011 |
Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition
Shibashish Giri, Augustinus Bader
|
Drug Discovery Today
|
2011 |
Induced pluripotent stem cells and regenerative medicine
Yuh-Chi Chen, Kung-Lin Tsai, Chia-Wei Hung, Dah-Ching Ding, Lih-Hsin Chen, Yuh-Lih Chang, Liang-Kung Chen, Shih-Hwa Chiou
|
Journal of Clinical Gerontology and Geriatrics
|
2011 |
Human-induced pluripotent stem cells as a source of hepatocyte-like cells: new kids on the block
C. Busletta, E. Novo, M. Parola
|
Hepatol Int
|
2011 |
|